Publicaciones en colaboración con investigadores/as de Complejo Hospitalario Torrecárdenas de Almería (26)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

2023

  1. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596

2022

  1. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

    Journal of Infection, Vol. 85, Núm. 3, pp. 322-326

2021

  1. Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

    Clinical Microbiology and Infection

2019

  1. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

  2. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54

  3. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  4. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks

    Journal of Infection, Vol. 79, Núm. 1, pp. 30-35

  5. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

    HIV Medicine, Vol. 20, Núm. 6, pp. 359-367

  6. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

  7. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51

  8. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort

    Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706

  2. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

    HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30

2017

  1. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

    HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134

  2. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

  3. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

  2. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort

    PLoS ONE, Vol. 11, Núm. 2

  3. No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014

    BMC Infectious Diseases, Vol. 16, Núm. 1